Belén Garijo, Merck KGaA CEO (Arne Dedert/picture alliance via Getty Images)

Mer­ck KGaA's bet on head and neck can­cer drug from De­bio­pharm ends in Phase 3 fail­ure

Mer­ck KGaA’s Phase 3 tri­als of xev­ina­pant, the can­cer drug it li­censed from De­bio­pharm in 2021, are wind­ing down af­ter the drug showed that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.